Ciltacabtagene autoleucel vs FT576
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation
NCT04181827 · Phase 3 · active, not recruiting
This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)
Result source: NCT04181827
FT576
Developed by Fate Therapeutics
NCT05182073 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD (Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1); Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts (From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)); Incidence, nature, and severity of adverse events (Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1): 12 patients were treated with a three-dose treatment schedule at 1 billion cells per dose (n=6) or 2.5 billion cells per dose (n=6). There were no dose-limiting toxicities and no events of any grade of CRS, ICANS or GvHD. Five of six (83%) heavily pre-treated patients achieved a clinical response at 1 billion cells per dose, including two penta-exposed patients treated with FT576 as monotherapy who achieved very good partial responses.
Result source: NCT05182073
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ciltacabtagene autoleucel | FT576 |
|---|---|---|
| PFS, median | —Trial running · NCT05257083 | —Not reported |
| OS, median | 27.0bNCT03548207 | —Not reported |
| ORR | 97.1%bNCT035482072 other results
| —Not reported |
| VGPR or better | 96.6%bNCT035482072 other results
| —Not reported |
| MRD negativity | 100%bNCT035482072 other results
| —Not reported |
PFS, median
- Ciltacabtagene autoleucel
- —Trial running · NCT05257083
- FT576
- —Not reported
OS, median
- Ciltacabtagene autoleucel
- 27.0bNCT03548207
- FT576
- —Not reported
ORR
- Ciltacabtagene autoleucel
- 97.1%bNCT03548207
2 other results
- 57.3% NCT05347485
- 100% NCT03548207
- FT576
- —Not reported
VGPR or better
- Ciltacabtagene autoleucel
- 96.6%bNCT03548207
2 other results
- 94.1% NCT03548207
- 100% NCT03548207
- FT576
- —Not reported
MRD negativity
- Ciltacabtagene autoleucel
- 100%bNCT03548207
2 other results
- 89.7% NCT03548207
- 75% NCT03548207
- FT576
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
FT576: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ciltacabtagene autoleucel: 2 of 4 rows · FT576: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ciltacabtagene autoleucel |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsn/a: no completion milestonePhase 1b (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (Japan Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestone NCT05347485 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results—Phase 1b (US Population) NCT03548207 · Phase 1/2 —Phase 2 (Japan Population) NCT03548207 · Phase 1/2 —Phase 2 (US Population) NCT03548207 · Phase 1/2 — NCT05347485 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 47.1%a NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results37.9%Phase 1b (US Population) NCT03548207 · Phase 1/2 11.1%Phase 2 (Japan Population) NCT03548207 · Phase 1/2 61.8%Phase 2 (US Population) NCT03548207 · Phase 1/2 51.2% NCT05347485 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a neutropenia 89.9% cytokine release syndrome 62% thrombocytopenia 54.3% NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsneutropenia 80.5% anaemia 59.8% cytokine release syndrome 57.3% NCT05347485 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ciltacabtagene autoleucel
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 27 more results
show 27 more results
show 27 more results
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · FT576's landscape